UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

**FORM 10-K/A Amendment No. 1**

 

(X) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934

 

**For the Fiscal Year Ended September 30, 2011**

 

OR

 

( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from **N/A** to **N/A**

Commission File Number: **000-28745**

 

**Cloud Medical Doctor Software Corporation**

(Name of small business issuer as specified in its charter)

(Formerly National Scientific Corporation)

 

** **

**1291 Galleria Drive, Suite 200**

**Henderson, NV 89014**

(Address of principal executive offices)

(Former Address 8361 East Evans Road, Suite 106, Scottsdale,AZ 85260-3617)

 

**(702) 818-9011**

(Issuer’s telephone number)

(Former telephone number (480) 948-8324)

 

**Securities registered under Section 12(b) of the ExchangeAct:**

**None**

**Securities registered under Section 12(g) of the ExchangeAct:**

**Common Stock, $0.001 par value per share**

(Title of Class)

**Common Stock, $.001 Par Value**

 

Indicate by check mark if the registrant is a well-known seasonedissuer, as defined in Rule 405 of the Securities Act. [ ] Yes [x] No

 

Indicate by check mark if the registrant is notrequired to file reports pursuant to Section 13 or Section 15(d) of the Act. [x] Yes [ ] No

 

Indicate by check mark whether the registrant (1) has filed all reports required to befiled by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periodthat the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes [ ] No [x]

 

Indicate by check mark whether the registranthas submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submittedand posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for suchshorter period that the registrant was required to submit and post such files). Yes [ ] No [x]

Indicate by check mark if disclosure of delinquentfilers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained,to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III ofthis Form 10-K or any amendment to this Form 10-K. [ ]

 

Indicate by check mark whether the registrant is a large acceleratedfiler, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large acceleratedfiler, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

 

Indicate by check mark whether the registrant is a shell company(as defined in Rule 12b–2 of the Exchange Act).  Yes [ ] No [x]

 

Aggregate market value of the voting stock held by non-affiliates:$5,087,389 as based on the closing price of the stock on September 26, 2013. The voting stock held by non-affiliates on that dateconsisted of 169,579,649 shares of common stock.

 

Indicate the number of shares outstanding of each of the registrant’sclasses of common stock, as of the latest practicable date. As of September 25, 2013, there were 214,634,216 shares of commonstock, par value $0.01, issued and outstanding 4,000,000 shares of preferred stock, par value $0.10.

 

**Documents Incorporated by Reference: None**

**EXPLANATORY NOTE**

 

This AmendmentNo. 1 on Form 10-K amends the Annual Reports on Form 10-K for the year ended September 30, 2011, filed on October 13, 2013and Form 10-K for the year ended September 30, 2012 filed on January 14, 2014 and for the year ended September 30, 2013 filedon February 15, 2014 (the “Original Reports”) filed by National Scientific Corporation (the “Company”)in response to an internal review by the company. The Company is amending disclosure in Item 10. Directors, Executive Officers,Promoters and Control Persons; Compliance with Section 16(a) 16(a) of the Exchange Act. The Company is amending this sectionto provide more detailed disclosure and extended disclosures to provide the shareholder more detailed information related to themanagement.

 

**I****tem10. Directors, Executive Officers, Promoters and Control Persons; Compliance with Section 16(a) 16(a) of the Exchange Act.**

 

Pamela Thompson

National ScientificCorporation, 2010-Present; *Chief Financial Officer and Director*

 

On February 25,2008, the Securities and Exchange Commission issued an administrative order against Ms. Thompson without Ms. Thompson admittingor denying the allegations.  Ms. Thompson was ordered to cease and desist from committing or causingany violations and any future violations of Sections 5(a), 5(c), 17(a)(2), and 17(a)(3) of the Securities Act and Section 17Aof the Exchange Act and Rule 17Ac2-1 and was barred from association with any transfer agent, with the right to reapply for associationafter three (3) years to the appropriate self-regulatory organization, or if there is none, to the Commission. She was also orderedto pay disgorgement of $7,632 and prejudgment interest of $830.82 to the United States Treasury.

 

The above information can be reviewed in itsentirety as ADMINISTRATIVE PROCEEDING File No. 3-12969 on the SEC website *www.sec.gov.*

**ITEM 15. EXHIBITS AND REPORTS.**

 

**Exhibits**

____________

** **

****

**SIGNATURES**

 

In accordance with Section 13 or 15(d) of the Securities ExchangeAct of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, there unto duly authorized.

 

 

 ** **

In accordance with the Securities Exchange Actof 1934, this report has been signed below by the following persons on behalf of the Company and in the capacities and on thedates indicated.

 

** **